SDZ 220-040CAS# 174575-40-7 |
- SB 431542
Catalog No.:BCC3658
CAS No.:301836-41-9
- SB-505124 hydrochloride
Catalog No.:BCC1930
CAS No.:356559-13-2
- SB525334
Catalog No.:BCC2531
CAS No.:356559-20-1
- LY2109761
Catalog No.:BCC3806
CAS No.:700874-71-1
- LY2157299
Catalog No.:BCC3709
CAS No.:700874-72-2
- A 83-01
Catalog No.:BCC1319
CAS No.:909910-43-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 174575-40-7 | SDF | Download SDF |
PubChem ID | 6604839 | Appearance | Powder |
Formula | C16H16Cl2NO6P | M.Wt | 420.19 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO | ||
Chemical Name | (2S)-2-amino-3-[5-(2,4-dichlorophenyl)-2-hydroxy-3-(phosphonomethyl)phenyl]propanoic acid | ||
SMILES | C1=CC(=C(C=C1Cl)Cl)C2=CC(=C(C(=C2)CP(=O)(O)O)O)CC(C(=O)O)N | ||
Standard InChIKey | NYZFUZCCDOSQBG-AWEZNQCLSA-N | ||
Standard InChI | InChI=1S/C16H16Cl2NO6P/c17-11-1-2-12(13(18)6-11)8-3-9(5-14(19)16(21)22)15(20)10(4-8)7-26(23,24)25/h1-4,6,14,20H,5,7,19H2,(H,21,22)(H2,23,24,25)/t14-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Potent competitive antagonist at the NMDA receptor (pKi = 8.5). Selective over a range of other receptor sites. |
SDZ 220-040 Dilution Calculator
SDZ 220-040 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.3799 mL | 11.8994 mL | 23.7988 mL | 47.5975 mL | 59.4969 mL |
5 mM | 0.476 mL | 2.3799 mL | 4.7598 mL | 9.5195 mL | 11.8994 mL |
10 mM | 0.238 mL | 1.1899 mL | 2.3799 mL | 4.7598 mL | 5.9497 mL |
50 mM | 0.0476 mL | 0.238 mL | 0.476 mL | 0.952 mL | 1.1899 mL |
100 mM | 0.0238 mL | 0.119 mL | 0.238 mL | 0.476 mL | 0.595 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- SDZ 220-581
Catalog No.:BCC1939
CAS No.:174575-17-8
- 2-Allylphenol
Catalog No.:BCC8518
CAS No.:1745-81-9
- alpha-Spinasterol glucoside
Catalog No.:BCN1120
CAS No.:1745-36-4
- Tipranavir
Catalog No.:BCC2002
CAS No.:174484-41-4
- Sanggenol A
Catalog No.:BCN3602
CAS No.:174423-30-4
- Amiloride HCl dihydrate
Catalog No.:BCC5068
CAS No.:17440-83-4
- Riluzole
Catalog No.:BCC3849
CAS No.:1744-22-5
- Tsugaric acid A
Catalog No.:BCN2980
CAS No.:174391-64-1
- Picropodophyllotoxin
Catalog No.:BCN2585
CAS No.:17434-18-3
- Astragaloside
Catalog No.:BCN5959
CAS No.:17429-69-5
- Caohuoside E
Catalog No.:BCN8198
CAS No.:174286-23-8
- Epimedin K
Catalog No.:BCN8201
CAS No.:174286-13-6
- SB 218795
Catalog No.:BCC7037
CAS No.:174635-53-1
- SB-222200
Catalog No.:BCC1926
CAS No.:174635-69-9
- Talnetant
Catalog No.:BCC1981
CAS No.:174636-32-9
- Phalloidin
Catalog No.:BCC7945
CAS No.:17466-45-4
- AN-2690
Catalog No.:BCC1360
CAS No.:174671-46-6
- CH 275
Catalog No.:BCC5913
CAS No.:174688-78-9
- 2-Amino-6-methoxybenzothiazole
Catalog No.:BCC8542
CAS No.:1747-60-0
- Ginsenoside Rh4
Catalog No.:BCN3503
CAS No.:174721-08-5
- Carabrone
Catalog No.:BCN1121
CAS No.:1748-81-8
- Fmoc-Hyp(Bzl)-OH
Catalog No.:BCC3255
CAS No.:174800-02-3
- 3-Amino-4-methoxybenzamide
Catalog No.:BCC8612
CAS No.:17481-27-5
- Rabdoketone B
Catalog No.:BCN6598
CAS No.:174819-51-3
Novel modulatory effects of SDZ 62-434 on inflammatory events in activated macrophage-like and monocytic cells.[Pubmed:18299817]
Naunyn Schmiedebergs Arch Pharmacol. 2008 Apr;377(2):111-24.
In this study, we investigated the novel pharmacological activity of SDZ 62-434 on various inflammatory events mediated by monocytes/macrophages (peritoneal macrophages and U937/RAW 264.7 cells) and its putative mechanism of action. SDZ 62-434 strongly inhibited various inflammatory responses induced by lipopolysaccharide (LPS) or function-activating antibody to CD29 (beta1-integrins) including (1) the production of human and mouse tumor necrosis factor (TNF)-alpha, (2) the generation of prostaglandin E(2) (PGE(2)), (3) the release of nitric oxide (NO) and reactive oxygen species (ROS), (4) the increased level of phagocytic uptake, (5) the up-regulation of surface costimulatory molecules CD80, CD86, and CD40, (6) functional activation of beta1-integrin (CD29) assessed by U937 cell-cell adhesion, and (7) the transcriptional up-regulation of inducible NO synthase (iNOS), TNF-alpha, cyclooxygenase (COX)-2, interleukin (IL)-1beta, and IL-6. The anti-inflammatory effects of SDZ 62-434 seem to be mediated by interrupting the early-activated intracellular signaling cascades composed of phosphoinositide 3-kinase (PI3K)/Akt and NF-kappaB but not Janus kinase-2 (JAK-2), extracellular signal-regulated kinase (ERK), p38, or C-Jun N-terminal kinase (JNK), according to pharmacological, biochemical and functional analyses. Therefore, these results suggest that SDZ 62-434 may have anti-inflammatory features derived from PI3K/Akt/NF-kappaB inhibitory activity.
[Comparative study on therapeutic effect between SXDZ-100 and SDZ-II on chronic functional constipation].[Pubmed:22295835]
Zhongguo Zhen Jiu. 2012 Jan;32(1):79-82.
OBJECTIVE: To compare the therapeutic effects between the Hwato neuro and muscle stimulator (SXDZ-100) and the regular electronic stimulator (SDZ-II) on chronic functional constipation. METHODS: Sixty-four cases of chronic functional constipation were randomly divided into a (SXDZ-100) observation group (n = 33) and SDZ-II control group (n = 31). For the SXDZ-100 group, under the considerations of patients' endurance, Zhigou(TE 6) and Tianshu (ST 25), Zusanli (ST 36) and Shangjuxu (ST 37) were punctured and then the courle of acupoints on the same side were connected with SXDZ-100 apparatus in reinforcing and reducing by twirling and rotating manipulation wave for 30 min, while in the control group SDZ-II apparatus was applied in the same way mentioned above with disperse-dense wave at frequency of 1Hz/20Hz for 30 min. By means of clinical therapeutic effect evaluation and clinical symptom score, the contrast between two groups can be made. RESULTS: Although the total effective rates were both 100.0%, the rate of short term effects in SXDZ-100 group (54.6%, 18/33) is significantly higher than that in SDZ-II group (29.0%, 9/31) (P < 0.05). After the treatment, the clinical symptom scores in both groups decreased significantly (both P < 0.05). And the therapeutic effective indices of the SXDZ-100 group were significantly higher than those of the SDZ- II group (P < 0.05). CONCLUSION: The therapeutic effect of Hwato neuro and muscle stimulator (SXDZ-100) on chronic functional constipation is superior to that of a regular electronic stimulator (SDZ-II).
Biphenyl-derivatives of 2-amino-7-phosphonoheptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonist--I. Pharmacological characterization in vitro.[Pubmed:8887974]
Neuropharmacology. 1996 Jun;35(6):643-54.
Omega-Phosphono-substituted alpha-amino acids have long been known to be antagonists at the N-methyl-D-aspartate (NMDA) receptor. D-2-Amino-5-phosphonopentanoic (D-AP5) and D-2-amino-7-phosphonoheptanoic (D-AP7) acids are the "prototype" compounds of this kind. Insertion of a biphenyl-moiety in the middle of the AP7 chain results in increased affinity and reverses the enantioselectivity from a D- to an L-form preference (Muller et al., (1992) Helv. Chim. Acta 75: 855-864). We describe here a series of substituted biphenyl-AP7-derivatives, the most potent of which have affinities (in a [3H]CGP-39653 binding assay using native and recombinant receptors) and potencies (antagonism of NMDA-induced depolarizations in a cortical wedge preparation; inhibition of glutamate-stimulated [3H]MK-801 binding under non-equilibrium conditions) in the low nanomolar range. Structure-activity relationships show that hydroxy-substitution at the C5-atom in the AP7-chain as well as substitution in the second phenyl ring with space filling (such as chloro-)groups in the para- and especially the ortho-position (extending the torsion angle of the two rings) increase affinity and potency of these compounds. They have no relevant affinities for the strychnine-insensitive glycine co-agonist site or the MK-801/PCP channel blocking site on the NMDA receptor complex. AMPA- and kainate-induced responses were not affected by biphenyl-analogues. These compounds also do not interact with a number of other neurotransmitter receptor sites, and they do not inhibit the uptake of [3H] glutamate in rat brain synaptosomes. However, they display affinities in the (sub)micromolar range for a non-NMDA, non-AMPA, non-kainate binding site for [3H]glutamate, measured in the presence of calcium chloride, the functional correlate of which has not yet been elucidated.
Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonists--II. Pharmacological characterization in vivo.[Pubmed:8887975]
Neuropharmacology. 1996 Jun;35(6):655-69.
A selection of biphenyl-analogues of 2-amino-7-phosphonoheptanoic acid (AP7), N-methyl-D-aspartate (NMDA) receptor antagonists with high affinity in vivo efficacy. The lead compound SDZ EAB 515 was found to inhibit L-phenylalanine uptake by the large neutral amino acid carrier in vitro and in vivo; active transport may thus confer a good bioavailability to this class of compounds. CNS effects were demonstrated by significant changes in 2-deoxyglucose-uptake in various brain regions at doses from 1 to 10 mg/kg i.p. With the most active agent, SDZ 220-581, full protection against maximal electroshock seizures (MES) was obtained at oral doses of 10 mg/kg in rats and in mice. The compound had a fast onset (< or = 1 hr) and a long duration (> or = 24 hr) of action. Motor-debilitating effects (impairment of rotarod performance) occurred at doses about 10 times higher than those required for protection against MES. Neuroprotective activity was demonstrated by the ability of the compounds to reduce the extent of quinolinic acid-induced striatal lesions in rats, in the dose range of 3-15 mg/kg (i.p.) or 10-50 mg/kg (p.o.). In the middle cerebral artery occlusion (MCAO) model of focal cerebral ischemia in rats, the test compounds reduced the infarct size by 40-50% when given i.v. before or by 20-30% when given i.v. 1 hr after MCAO. SDZ 220-581 provided 20-30% protection at > or = 2 x 10 mg/kg p.o. This compound also showed analgesic activity at low oral doses in a model of neuropathic pain, although higher doses were required in model of mechanical inflammatory hyperalgesia. Unexpectedly, SDZ 220-581 at low s.c. doses counteracted the antiparkinsonian effects of L-DOPA in MPTP-treated marmosets. (Sub)chronic administration of SDZ 220-581 did not reduce its ability to protect against quinolinic acid neurotoxicity, and no upregulation of NMDA receptors was detected using a [3H]CGP-39653 binding assay. In conclusion, from a series of biphenyl-AP7-derivatives, SDZ 220-581 is clearly the most active compound in vivo. Its pharmacological profile with a good, long-lasting oral activity might open up novel therapeutic applications for competitive NMDA receptor antagonists.